Last reviewed · How we verify

Mucositis following radiation therapy — Treatment Landscape & Competitive Intelligence

Mucositis following radiation therapy (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Mucositis following radiation therapy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Kepivance PALIFERMIN Biovitrum Ab Mucocutaneous Epithelial Cell Growth Factor [EPC] Fibroblast growth factor receptor 2 2004-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Biovitrum Ab · 1 drug in Mucositis following radiation therapy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Mucositis following radiation therapy:

Cite this brief

Drug Landscape (2026). Mucositis following radiation therapy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/mucositis-following-radiation-therapy. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing